Esomeprazole chemical structure
Find information on thousands of medical conditions and prescription drugs.

Nexium

Esomeprazole (IPA: ) is a proton pump inhibitor used in the treatment of dyspepsia, peptic ulcer disease (PUD), GERD and Zollinger-Ellison syndrome. Esomeprazole magnesium trihydrate is marketed by AstraZeneca under the tradename Nexium. Esomeprazole is the S-enantiomer of omeprazole (marketed as Losec/Prilosec), and AstraZeneca claims improved efficacy of this single enantiomer product over the racemic mixture of omeprazole (see below). more...

Home
Diseases
Medicines
A
B
C
D
E
F
G
H
I
J
K
L
M
N
Nabilone
Nadolol
Nafarelin
Nafcillin
Nalbuphine
Nalidixic acid
Nallpen
Naloxone
Naltrexone
Nandrolone
Naphazoline
Naprelan
Naprosyn
Naproxen
Naratriptan
Narcan
Nardil
Naropin
Nasacort
Nasalcrom
Nascobal
Natamycin
Navane
Navelbine
Nebcin
Nebracetam
Nefazodone
Nefiracetam
Nelfinavir
Nembutal
Neoarsphenamine
Neomycin
Neoral
Neosporin
Neulasta
Neupogen
Neurontin
Nevirapine
Nexium
Nialamide
Niaspan
Niclosamide
Nicoderm
Nicorette
Nicotinamide
Nicotine
Nicotinic acid
Nicotrol
Nifedipine
Nifehexal
Nikethamide
Nilstat
Nilutamide
Nimesulide
Nimodipine
Nimotop
Nitrazepam
Nitrofurantoin
Nix
Nizatidine
Nizoral
Nocodazole
Nolvadex
Nomifensine
Norco
Nordazepam
Nordette
Norepinephrine
Norethin
Norfloxacin
Norgestimate
Norgestrel
Norinyl
Noritate
Normodyne
Norplant
Norpramin
Nortriptyline
Norvasc
Norvir
Noscapine
Novafed
Novobiocin
Novocain
Novrad
Nuprin
Nysert
Nystaform
Nystatin
Nystex
Nystop
O
P
Q
R
S
T
U
V
W
X
Y
Z

Pharmacology

Esomeprazole is a proton pump inhibitor which reduces gastric acid secretion through inhibition of H+/K+-ATPase in gastric parietal cells. By inhibiting the functioning of this enzyme, the drug prevents formation of gastric acid.

Clinical use

Use in Helicobacter pylori eradication

Esomeprazole is combined with the antibiotics clarithromycin and amoxicillin (or metronidazole in penicillin-hypersensitive patients) in the one week eradication triple therapy for Helicobacter pylori. Infection by H. pylori is the causative factor in the majority of peptic and duodenal ulcers.

Evidence of efficacy

AstraZeneca claims that esomeprazole provides improved efficacy, in terms of stomach acid control, over racemic omeprazole. Many health professionals have expressed the view that this improvement in efficacy is due to the increased dose of (es)omeprazole recommended for therapy rather than any superiority of esomeprazole per se.

The study usually cited by AstraZeneca to support its claims is of doubtful study power. Lind et al. (2004) compared esomeprazole to omeprazole in a study of only 36 GERD patients. It is noted that this study was financially supported by AstraZeneca itself.

An alternative rationale suggested for the use of esomeprazole was the reduction in interindividual variability in efficacy. There is, however, little evidence for even this advantage. (Somogyi et al., 2004)

Given the large difference in cost between esomeprazole and other proton pump inhibitors and the negligible advantages of esomeprazole, many doctors recommend cheaper alternatives, which in most cases work just as well.

Dosage forms

Esomeprazole is available as delayed-release tablets (containing esomeprazole magnesium) in strengths of 20 mg and 40 mg; and as a powder (esomeprazole sodium) for intravenous injection/infusion. Oral esomeprazole preparations are enteric-coated, due to the rapid degradation of the drug in the acidic conditions of the stomach. This is achieved by formulating tablets using the multiple-unit pellet system.

Multiple unit pellet system

Esomeprazole tablets are formulated as a "multiple unit pellet system" (MUPS). Essentially, the tablet consists of extremely small enteric-coated granules (pellets) of the esomeprazole formulation inside an outer shell. When the tablet is immersed in an aqueous solution, as happens when the tablet reaches the stomach, water enters the tablet by osmosis. The contents swell from water absorption causing the shell to burst, releasing the enteric-coated granules. For most patients, the multiple-unit pellet system is of no advantage over conventional enteric-coated preparations. Patients for which the formulation is of benefit include those requiring nasogastric tube feeding and those with difficulty swallowing (dysphagia).

Read more at Wikipedia.org


[List your site here Free!]




Home Contact Resources Exchange Links ebay